Christine M Durand

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8428762/publications.pdf

Version: 2024-02-01

100 papers	5,012 citations	147801 31 h-index	95266 68 g-index
101 all docs	101 docs citations	101 times ranked	6249 citing authors

#	Article	IF	Citations
1	Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation. Immunity, 2012, 36, 491-501.	14.3	680
2	Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature, 2015, 517, 381-385.	27.8	469
3	New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature Medicine, 2014, 20, 425-429.	30.7	436
4	Ex vivo analysis identifies effective HIV-1 latencyâ€“reversing drug combinations. Journal of Clinical Investigation, 2015, 125, 1901-1912.	8.2	340
5	Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virusâ€“Infected Donors to Noninfected Recipients. Annals of Internal Medicine, 2018, 168, 533.	3.9	258
6	Early impact of COVID-19 on transplant center practices and policies in the United States. American Journal of Transplantation, 2020, 20, 1809-1818.	4.7	214
7	The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States. Annals of Internal Medicine, 2018, 168, 702.	3.9	169
8	Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection. Immunity, 2017, 47, 766-775.e3.	14.3	160
9	The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood, 2016, 127, 2007-2017.	1.4	158
10	Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. Journal of Clinical Investigation, 2013, 123, 3848-3860.	8.2	120
11	HIV-1 DNA Is Detected in Bone Marrow Populations Containing CD4+ T Cells but Is not Found in Purified CD34+ Hematopoietic Progenitor Cells in Most Patients on Antiretroviral Therapy. Journal of Infectious Diseases, 2012, 205, 1014-1018.	4.0	102
12	Changes in Utilization and Discard of Hepatitis Câ€“Infected Donor Livers in the Recent Era. American Journal of Transplantation, 2017, 17, 519-527.	4.7	95
13	Developing strategies for HIV-1 eradication. Trends in Immunology, 2012, 33, 554-562.	6.8	87
14	Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. Aids, 2021, 35, 2399-2401.	2.2	76
15	Single-cell transcriptional landscapes reveal HIV-1â€“driven aberrant host gene transcription as a potential therapeutic target. Science Translational Medicine, 2020, 12, .	12.4	75
16	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transplantation, 2016, 22, 446-458.	2.4	73
17	Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. Journal of Clinical Investigation, 2017, 127, 651-656.	8.2	64
18	Detection of Cytomegalovirus DNA in Plasma as an Adjunct Diagnostic for Gastrointestinal Tract Disease in Kidney and Liver Transplant Recipients. Clinical Infectious Diseases, 2013, 57, 1550-1559.	5.8	63

#	Article	IF	Citations
19	Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic. American Journal of Transplantation, 2020, 20, 3131-3139.	4.7	57
20	A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action. American Journal of Transplantation, 2021, 21, 1754-1764.	4.7	56
21	Multicenter Study to Transplant Hepatitis Câ€“Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. Journal of the American Society of Nephrology: JASN, 2020, 31, 2678-2687.	6.1	55
22	Realizing HOPE: The Ethics of Organ Transplantation From HIV-Positive Donors. Annals of Internal Medicine, 2016, 165, 138.	3.9	50
23	Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study. American Journal of Transplantation, 2020, 20, 2997-3007.	4.7	50
24	No recovery of replication-competent HIV-1 from human liver macrophages. Journal of Clinical Investigation, 2018, 128, 4501-4509.	8.2	41
25	Epsteinâ€“Barr virus and renal transplantation. Transplantation Reviews, 2017, 31, 55-60.	2.9	39
26	Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood, 2020, 136, 1284-1297.	1.4	39
27	Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses. American Journal of Transplantation, 2021, 21, 1838-1847.	4.7	39
28	Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 596-604.	6.4	38
29	Pasteurella multocida infection in solid organ transplantation. Lancet Infectious Diseases, The, 2015, 15, 235-240.	9.1	38
30	Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis Câ€“Viremic Donors to Hepatitis Câ€“Negative Recipients: An Open-Label Nonrandomized Study. Annals of Internal Medicine, 2021, 174, 137-138.	3.9	38
31	Early Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic. Transplantation, 2021, 105, 170-176.	1.0	37
32	Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy. Transplantation, 2018, 102, 2088-2095.	1.0	36
33	Hepatitis Câ€positive donor liver transplantation for hepatitis C seronegative recipients. Transplant Infectious Disease, 2019, 21, e13194.	1.7	33
34	Utilization of hepatitis C virus RNAâ€“positive donor liver for transplant to hepatitis C virus RNAâ€“negative recipient. Liver Transplantation, 2018, 24, 140-143.	2.4	32
35	Knowledge, attitudes, and planned practice of <scp>HIV</scp>â€positive to <scp>HIV</scp>â€positive transplantation in <scp>US</scp> transplant centers. Clinical Transplantation, 2018, 32, e13365.	1.6	31
36	Organs from deceased donors with false-positive HIV screening tests: An unexpected benefit of the HOPE act. American Journal of Transplantation, 2018, 18, 2579-2586.	4.7	30

#	Article	IF	Citations
37	HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV. American Journal of Transplantation, 2022, 22, 853-864.	4.7	30
38	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. Biology of Blood and Marrow Transplantation, 2019, 25, 2160-2166.	2.0	27
39	Characterizing the landscape and impact of infections following kidney transplantation. American Journal of Transplantation, 2021, 21, 198-207.	4.7	27
40	Moving from the HIV Organ Policy Equity Act to HIV Organ Policy Equity in action. Current Opinion in Organ Transplantation, 2018, 23, 271-278.	1.6	26
41	Willingness to Donate Organs Among People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, e30-e36.	2.1	26
42	Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational study. Lancet HIV,the, 2020, 7, e611-e619.	4.7	25
43	Evolving Impact of COVIDâ€19 on Transplant Center Practices and Policies in the United States. Clinical Transplantation, 2020, 34, e14086.	1.6	24
44	Solid Organ Transplantation for HIV-Infected Individuals. Current Treatment Options in Infectious Diseases, 2018, 10, 107-120.	1.9	23
45	Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers. Current HIV/AIDS Reports, 2019, 16, 191-203.	3.1	21
46	Effects of COVID-19 pandemic on pediatric kidney transplant in the United States. Pediatric Nephrology, 2021, 36, 143-151.	1.7	20
47	Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium. Transplantation, 2021, 105, 216-224.	1.0	18
48	Lessons from the real world: HCV-infected donor kidney transplantation as standard practice. American Journal of Transplantation, 2019, 19, 2969-2970.	4.7	16
49	Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma. Hepatology, 2017, 66, 661-663.	7.3	15
50	<scp>HIV</scp>+ deceased donor referrals: A national survey of organ procurement organizations. Clinical Transplantation, 2018, 32, e13171.	1.6	14
51	Haemopoietic cell transplantation in patients living with HIV. Lancet HIV,the, 2020, 7, e652-e660.	4.7	14
52	Similar Frequency and Inducibility of Intact Human Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. Journal of Infectious Diseases, 2020, 224, 258-268.	4.0	14
53	Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease preâ€“ or postâ€“liver transplant. American Journal of Transplantation, 2021, 21, 1780-1788.	4.7	14
54	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. Transplantation Direct, 2022, 8, e1268.	1.6	14

#	Article	IF	Citations
55	The future of HIV Organ Policy Equity Act is now. Current Opinion in Organ Transplantation, 2019, 24, 434-440.	1.6	13
56	Clarifying the HOPE Act landscape: The challenge of donors with falseâ€positive HIV results. American Journal of Transplantation, 2020, 20, 617-619.	4.7	13
57	Brief Report: Willingness to Accept HIV-Infected and Increased Infectious Risk Donor Organs Among Transplant Candidates Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 88-92.	2.1	13
58	Hematopoietic stem cell transplantation in HIV-1-infected individuals. Current Opinion in Oncology, 2013, 25, 180-186.	2.4	12
59	Pro: Use of Hepatitis C Virusâ€“Positive Donors Should Be Considered Standard of Care. Clinical Liver Disease, 2018, 12, 100-104.	2.1	12
60	Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. Transplant Infectious Disease, 2018, 20, e12982.	1.7	12
61	Public discourse and policy change: Absence of harm from increased oversight and transparency in OPO performance. American Journal of Transplantation, 2021, 21, 2646-2652.	4.7	12
62	HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia. Aids, 2010, 24, 2405-2408.	2.2	12
63	One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial. Kidney International Reports, 2022, 7, 241-250.	0.8	12
64	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV,the, 2020, 7, e602-e610.	4.7	11
65	Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine. Transplantation Direct, 2021, 7, e713.	1.6	11
66	Perceptions, motivations, and concerns about living organ donation among people living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1595-1599.	1.2	10
67	Patientâ€™s Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site. AJOB Empirical Bioethics, 2020, 11, 40-52.	1.6	10
68	Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. Journal of Clinical Virology, 2011, 51, 195-198.	3.1	9
69	Science Over Stigma: Lessons and Future Direction of HIV-to-HIV Transplantation. Current Transplantation Reports, 2021, 8, 314-323.	2.0	9
70	Dual zinc-finger nucleases block HIV infection. Blood, 2014, 123, 2-3.	1.4	8
71	Challenges in solid organ transplantation in people living with HIV. Intensive Care Medicine, 2019, 45, 398-400.	8.2	8
72	National Landscape of Human Immunodeficiency Virusâ€“Positive Deceased Organ Donors in the United States. Clinical Infectious Diseases, 2022, 74, 2010-2019.	5.8	7

#	Article	IF	Citations
73	HIV and Stem Cell Transplantation. Current Infectious Disease Reports, 2014, 16, 424.	3.0	6
74	False-positive hepatitis C virus serology after placement of a ventricular assistance device. Transplant Infectious Disease, 2016, 18, 146-149.	1.7	6
75	With Jaundiced Eyes. American Journal of Medicine, 2009, 122, 21-23.	1.5	5
76	Antithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients With Hepatitis C Virus. Transplantation, 2020, 104, 1294-1303.	1.0	5
77	Early steroid withdrawal in HIV-infected kidney transplant recipients: Utilization and outcomes. American Journal of Transplantation, 2021, 21, 717-726.	4.7	5
78	Potential donor characteristics and decisions made by organ procurement organization staff: Results of a discrete choice experiment. Transplant Infectious Disease, 2021, 23, e13721.	1.7	5
79	Increasing the Donor Pool: Organ Transplantation from Donors with HIV to Recipients with HIV. Annual Review of Medicine, 2021, 72, 107-118.	12.2	4
80	Expanding the Use of Organs From Hepatitis C-Viremic Donors. Transplantation, 2018, 102, 546-547.	1.0	4
81	Implications of Treating Hepatitis C Virus Infection Among Patients Awaiting Cadaveric Liver Transplant: A Single-Center Experience. Experimental and Clinical Transplantation, 2015, 13, 7-10.	0.5	4
82	A Human Immunodeficiency Virus Controller With a Large Population of CD4+CD8+ Double-Positive T Cells. Open Forum Infectious Diseases, 2015, 2, ofv039.	0.9	3
83	Antimicrobial Access in the 21st Century: Delays and Critical Shortages. Annals of Internal Medicine, 2016, 165, 53.	3.9	3
84	Early experiences of independent advocates for potential HIV+ recipients of HIV+ donor organ transplants. Clinical Transplantation, 2019, 33, e13617.	1.6	3
85	Early Experiences With COVID-19 Testing in Transplantation. Transplantation Direct, 2020, 6, e572.	1.6	3
86	Reclaiming missed opportunities: a strategy of targeted directâ€acting antiviral prophylaxis for HCVâ€seronegative recipients of HCVâ€seropositive donor kidneys. Transplant International, 2019, 32, 690-692.	1.6	2
87	Single-Center Experience in Pre-transplant Hepatitis C Virus (HCV) Treatment Among Living Donor Liver Transplant Candidates: Bridging the Direct-Acting Antivirals (DAA). Annals of Transplantation, 2017, 22, 570-574.	0.9	2
88	Donors with human immunodeficiency virus and hepatitis C virus for solid organ transplantation: what's new. Current Opinion in Infectious Diseases, 2022, 35, 321-329.	3.1	2
89	Hepatitis C following liver transplantation. Current Opinion in Infectious Diseases, 2016, 29, 346-352.	3.1	1
90	Living Kidney Donation in Individuals with Hepatitis C and HIV Infection: Rationale and Emerging Evidence. Current Transplantation Reports, 2019, 6, 167-176.	2.0	1

#	Article	IF	Citations
91	Pretransplant Hepatitis C Virus Treatment Decreases Access to High-quality Livers. Transplantation Direct, 2021, 7, e684.	1.6	1
92	Clearing the hepatitis hurdle: Obstacles and opportunities in liver transplantation for people with HIV. American Journal of Transplantation, 2021, 21, 2931-2932.	4.7	1
93	Patientsâ€™ Experiences With HIV-positive to HIV-positive Organ Transplantation. Transplantation Direct, 2021, 7, e745.	1.6	1
94	New modalities in the treatment of HCV in pre and post - transplantation setting. Turkish Journal of Gastroenterology, 2015, 26, 204-213.	1.1	1
95	Bypassing the bottleneck: intentional hepatitis C transmission with organ transplant. Journal of Clinical Investigation, 2019, 129, 3038-3040.	8.2	1
96	Rebound HIV viremia with meningoencephalitis following antiretroviral therapy interruption after allogeneic bone marrow transplant. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, .	2.1	1
97	A 70-Year-Old Kidney Transplant Recipient Presenting With Persistent Leg Cellulitis. Clinical Infectious Diseases, 2014, 59, 688-688.	5.8	0
98	Reply. Hepatology, 2018, 67, 1183-1184.	7.3	0
99	Development of a Patient Reported Measure of Experimental Transplants with HIV and Ethics in the United States (PROMETHEUS). Journal of Patient-Reported Outcomes, 2021, 5, 28.	1.9	0
100	Persistence of HIV after allogeneic bone marrow transplant in a dually-infected individual. AIDS Research and Human Retroviruses, 2021, , .	1.1	0